What JUVÉDERM Ultra Plus Treats: Main Uses and Benefits

JUVÉDERM Ultra Plus is considered relevant in situations involving the visible management of moderate to severe facial wrinkles and folds. It is commonly used to help address structural deficits in aesthetic medicine, specifically targeting deep depressions like nasolabial folds and marionette lines, as well as providing substantial augmentation for thinning lips.

JUVÉDERM Ultra Plus is specifically applied in clinical scenarios involving significant, static skin depressions. This application provides supportive relief that assists with maintaining functional stability of the facial structure. The product is applied across conditions presenting with substantial soft tissue atrophy, helping to ease the overall symptom load of pronounced signs of aging.

“It is relevant when supportive symptom management is appropriate, particularly where volume deficit symptoms create noticeable physiological strain on facial contours.”

---

Quick Fact: Relief for Deep Volume Deficit This product is commonly used to address symptoms related to significant age-related soft tissue atrophy, such as lower cheek hollowing, contributing to improved comfort during symptomatic periods.

---

Regulatory References

1. FDA Directions for Use for JUVÉDERM Ultra Plus XC

The official regulatory profile for JUVÉDERM Ultra Plus defines patient eligibility primarily through absolute contraindications and population limitations where safety is not established.

Contraindicated Populations

Use is strictly prohibited for individuals with a history of severe allergies, particularly those with a history of anaphylaxis or the presence of multiple severe allergies. The product is also contraindicated for patients with known allergies to the local anesthetic lidocaine or to the Gram-positive bacterial proteins utilized in the gel's manufacturing process.

Conditional Use and Safety Limitations

• Active Site Conditions: Treatment must be deferred if an active inflammatory process (such as a rash) or infection is present at the proposed injection site.
• Immune Status: Caution is required for patients undergoing immunosuppressive therapy, as use may increase the risk of infection.
• Bleeding Risk: Caution is advised for patients using medications that can prolong bleeding (e.g., aspirin or NSAIDs), which may result in increased bruising or bleeding.
• Age and Physiological Status: Safety has not been established for patients under 18 years of age, or for pregnant or breastfeeding females.
• Scarring Risk: Safety has not been studied in individuals with a known susceptibility to keloid formation, hypertrophic scarring, or pigmentation disorders.

Interactions with other medicines and products

Official regulatory documentation identifies specific product categories and procedures that may interact with Juvederm Ultra Plus, necessitating caution or prescribing constraints.

---

Potential Interaction Categories

Interacting Product/Category	Practical Constraint/Implication
Substances that prolong bleeding (e.g., Warfarin, NSAIDs, Acetylsalicylic acid)	May lead to increased bruising or bleeding at the injection sites. Use with caution.
Active Dermal Response Procedures (e.g., laser treatment, chemical peeling)	Risk of eliciting an inflammatory reaction at the implant site if performed shortly before or after treatment.
Immunosuppressive Therapy	Use with caution due to potential effects on the body's response to the implant.
Quaternary Ammonium Salts (e.g., Benzalkonium chloride)	Incompatible with the hyaluronic acid component; never allow contact with the product or treated instruments.

---

Lidocaine-Related Drug Interactions

The lidocaine component of Juvederm Ultra Plus introduces additional interaction considerations related to hepatic metabolism.

Concomitant use with certain drugs known to reduce or inhibit hepatic metabolism, such as Cimetidine and Beta-blockers, is not recommended. These combinations may increase the systemic exposure to lidocaine, and should be considered by healthcare providers when evaluating patient history.

The mechanism of action for JUVÉDERM Ultra Plus involves a dual-component process: a primary biophysical action contributing to structural integrity and a secondary pharmacological action that results in transient sensory nerve conduction blockade.

Structural Support via Biophysical Volume Displacement

The primary mechanism involves the injection of cross-linked Sodium Hyaluronate, a viscoelastic gel that physically displaces soft tissue within the Extracellular Matrix (ECM). The high density and chemical cross-linking of the polymer chains introduce immediate physical volume and impart resistance to depolymerization by enzymes like endogenous Hyaluronidase.

Furthermore, the gel's hydrophilic nature attracts and binds surrounding water molecules, leading to enhanced local tissue turgor and influencing the persistence of the implant.

Transient Inhibition of Peripheral Nociceptive Signaling

The secondary mechanism is delivered by the incorporated Lidocaine Hydrochloride, which acts on the peripheral Nociceptive Signaling Pathway. Lidocaine targets and reversibly blocks Voltage-Gated Sodium Channels ( Na^+ Channels) on sensory nerve membranes. This channel blockade prevents the necessary influx of Na^+ ions, thereby inhibiting the generation and propagation of action potentials, which results in a rapid, transient inhibition of peripheral nerve signal transmission at the site of action.

How to Use Juvéderm Ultra Plus — Administration Guidelines

Juvéderm Ultra Plus injectable gel is a sterile dermal filler that must be administered only by authorized healthcare professionals who have specific training and experience in injection techniques. The administration is governed by defined procedural rules and dosing limits.

Administration Scope

Instruction Domain	Guidelines
Route of Administration	Injection into the mid to deep dermis. Must not be injected into blood vessels (intravascular).
Dosing Schedule	The volume injected should achieve 100% of the desired effect, avoiding overcorrection. Patients should be limited to 20 mL of any Juvéderm injectable gel per 60 kg body mass per year.
Frequency and Timing	The duration of correction is approximately one year, after which follow-up injections may be required to maintain optimal results.
Age-Group Rules	The safety and effectiveness for use in patients under 18 years of age has not been established.

Procedural and Handling Requirements

Instruction Domain	Guidelines
Preparation	The product is designed to be used as supplied in the pre-filled syringe; it must not be modified or resterilized.
Injection Technique	Inject the product slowly and apply the least amount of pressure necessary. An aspiration check (withdrawing the plunger slightly before injection) is recommended to verify the needle is not intravascular.
Post-Procedure	Patients should avoid strenuous exercise, extensive sun or heat exposure, and alcoholic beverages within the first 24 hours following treatment.

Procedural Structure

Proper use dictates the following sequence: the supplied 27 G needle must be attached securely to the single-patient syringe; the injector should perform aspiration to ensure correct placement; the gel must be implanted slowly into the deep dermal layer; and the total volume administered must remain within the annual maximum volume limit. Product use must be deferred at sites presenting an active inflammatory process or infection.

These instructions define the standardized procedural protocol for using the dermal filler, ensuring the product's defined characteristics, such as the 24 mg/mL concentration, are administered according to established rules for placement and volume.

Recent Clinical Evidence: Juvederm Ultra Plus

This section outlines the findings of clinical studies that evaluated the compound’s effects for correcting moderate to severe facial wrinkles and folds, and for lip augmentation.

Research Population and Scope

Clinical research involving Juvederm Ultra Plus focused on adult participants seeking volume restoration in the mid-to-lower face and/or lip enhancement. The studies assessed clinical outcomes following the compound's administration into the dermal tissues.

• Targets of Investigation: Trials investigated the compound's ability to provide temporary correction for facial folds, primarily the nasolabial folds (NLFs).
• Research Demographics: Studies included diverse adult populations to evaluate the performance and tolerability of the compound across various skin types and ages.

Key Clinical Findings

Research has evaluated the effects in randomized controlled trials (RCTs) involving participants with moderate to severe facial wrinkles and folds.

Primary Study Data

• Study Data: RCT findings generally report that participants achieved a clinically meaningful improvement on validated NLF severity scales compared to baseline. Observed duration of effect has varied across studies, with correction lasting approximately one year in many participants.
• Research Administration: The clinical trials followed strict administration protocols to assess product performance and safety.

Other Findings and Ongoing Research

• Quality of Life: Secondary endpoint analysis has included investigation of patient-reported outcomes related to appearance satisfaction.
• Long-Term Monitoring: Ongoing post-market surveillance and observational studies continue to examine the compound's profile over extended periods.

Key Studies & References

1. Safety and effectiveness of a new hyaluronic acid filler in the correction of moderate to severe nasolabial folds: a 12-month study

Common questions about Juvederm Ultra Plus (FAQ)

Q: What are the approved uses of Juvederm Ultra Plus by regulatory bodies?

A: According to official product information, Juvederm Ultra Plus injectable gel is indicated for injection into the mid to deep layers of the skin (dermis).

Its approved use is for the correction of moderate to severe facial wrinkles and folds, such as the lines that run from the nose to the corners of the mouth (nasolabial folds).

---

Q: What is the general function of Juvederm Ultra Plus once injected into the skin?

A: The product is a viscoelastic gel, meaning it is a thick, flowable substance. The general function is a biophysical process where the gel physically displaces soft tissue within the skin's structure.

This volume displacement is intended to temporarily replace soft tissue volume and provide structural support at the site of injection.

---

Q: Is the product used to address volume loss or surface lines?

A: Official information indicates the product is approved for the correction of moderate to severe facial wrinkles and folds.

Because the gel has high structural density, it is typically described as suitable for areas requiring firmer support, which often corresponds to volume replacement rather than treatment of very superficial lines.

---

Q: How long does the cosmetic effect of Juvederm Ultra Plus typically last based on clinical reports?

A: Clinical trials and patient information indicate that the observed duration of the effect lasts approximately one year (12 months) in many participants.

This is the timeframe cited in the official documents regarding the observed persistence of the product.

---

Q: What general factors are described in research as influencing how long Juvederm Ultra Plus remains in the tissue?

A: Studies and general product characteristics suggest that the duration of the effect can be influenced by several factors.

These factors include the individual's metabolic rate of the hyaluronic acid, the specific area of injection, and other patient-specific variables.

---

Q: Is the reported longevity of Juvederm Ultra Plus the same for all treatment areas?

A: Official information indicates that the longevity of the product can vary depending on the area of treatment.

Areas of the face that experience more frequent or intense muscle movement may process or break down the filler substance more quickly than less active areas.

---

Q: What is the typical timeframe for follow-up treatment described in patient information?

A: The official duration of correction is reported to be approximately one year.

Follow-up injections may be required after this timeframe to maintain the desired cosmetic result.

---

Q: Is it common to notice temporary firmness or small lumps/bumps at the injection site after a procedure?

A: Yes, common injection site reactions include firmness, induration (hardening), and the presence of small lumps or bumps.

These are temporary reactions, and official sources indicate they typically resolve spontaneously within one to two weeks following the procedure.

---

Q: What are the official warnings regarding potential signs of a delayed inflammatory reaction after treatment?

A: Official product labeling contains statements regarding inflammatory reactions that persist for more than one week.

Any unexpected or persistent side effect is important to communicate to the treating medical professional promptly.

---

Q: What is the 'Tyndall effect' as it relates to hyaluronic acid fillers like Juvederm Ultra Plus?

A: The Tyndall effect refers to an effect where the injection site may appear to have a bluish-gray discoloration or staining.

This effect is specifically noted in official documents as a possibility, especially if the hyaluronic acid filler is placed too superficially or in very thin skin.

---

Q: Can patients with a history of excessive scarring, like keloids, use Juvederm Ultra Plus?

A: According to the official prescribing information, the safety of Juvederm Ultra Plus has not been studied in individuals known to be susceptible to keloid formation (excessive scarring) or hypertrophic scarring.

This means there is no established data to confirm the product's safety for this patient population.

---

Q: What does the product information say about using Juvederm Ultra Plus in patients with pigmentation disorders?

A: The official product information states that the safety of Juvederm Ultra Plus has not been studied in individuals with pigmentation disorders.

This means there is no established data to confirm the product's safety profile for this group.

---

Q: Can other fillers be used in the same general area as Juvederm Ultra Plus?

A: Official safety precautions advise patients to inform their healthcare professional if they have previously been injected with any other type of dermal filler in the area being considered for treatment.

This information is important for the medical professional to consider before proceeding with the treatment.

---

Q: What is the general difference in gel consistency between Juvederm Ultra Plus and Juvederm Ultra?

A: Juvederm Ultra Plus is generally described as a thicker, more viscous gel with greater structural density compared to the Juvederm Ultra formulation.

This difference in density and stability is primarily due to the Ultra Plus formulation having a higher degree of cross-linking of the hyaluronic acid component.

---

Q: How soon after the procedure do official sources indicate the full cosmetic result of Juvederm Ultra Plus can be assessed?

A: While immediate volume changes are often visible, the injection site often experiences temporary swelling and other side effects that can affect the initial appearance.

Clinical study information suggests that the final, settled cosmetic result is typically assessed two to four weeks following the treatment, once initial reactions have subsided.

---

Q: What is the recommended time to wait before applying makeup to the treated area?

A: Official guidance indicates that the application of makeup to the treated area is generally avoided for the first 12 hours following the injection procedure.

This is cited as a general post-treatment precaution to minimize the risk of irritation or interference with the injection sites.

Official Storage and Disposal Profile: JUVÉDERM® Ultra Plus

The storage and disposal requirements for JUVÉDERM® Ultra Plus are strictly defined by regulatory labeling to maintain product sterility and safety.

Storage Requirement	Official Constraint
Temperature	Store between 2 C and 25 C.
Handling	Must be used as supplied. Do not resterilize.
Package Integrity	Do not use if the package is damaged or if the syringe content appears cloudy or separated.
Use Limitation	Packaged for single-patient use only.

Disposal of Used Materials

Used syringes and needles are classified as potential biohazards. Their disposal must adhere to accepted medical practice and comply with all applicable local, state, and federal regulatory requirements for medical waste.